Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-04-19
2011-04-19
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100
Reexamination Certificate
active
07927592
ABSTRACT:
The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2and Fv,b small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5861156 (1999-01-01), George et al.
patent: WO 9609043 (1996-03-01), None
Frank, MM et al. In Fundamental Immunology, 2nd Edition, ed. by W. Paul, Raven Press, New York, pp. 679-701.
Brouwer, N. et al. Molecular Immunology [2006] 43:2051-2060.
Lambris et al. Nature Review Microbiology, 2008, 6:132-142.
Anderson, et al. “A Monoclonal Antibody Against Human Complement Component C2”, Biochem. Soc. Trans., 1987, vol. 15. No. 4. pp. 660-661.
Chikako, et al. “Monoclonal Anti-Human C4b Antibodies: Stabilization and Inhibition of the Classical Pathway C3 Convertase”, Molecular Immunology, 1986, vol. 23, No. 2, pp. 151-157.
Inal et al. “Schistosoma TOR (trispanning orphan receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite”, Biochem. Biophys. ACTA 14445(3):283-298 (Jun. 1999).
Inal et al. “A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2”, FEBS Letter 470:131-134 (2000).
Janeway et al. Immunobiology, 3rdEd., Current Biology Ltd. England, 1997, pp. 133:7-8.
Vakeva et al. “Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy”, Circulation 97:2259-2267 (Jun. 1998).
Stoltzner et al. “Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease”, Am J Pathol. 156(2):489-499, 2000.
M. Matsushita, “The Lectin Pathway of the Complement System”, Microbiol. Immunol. 40(12):887-893 (1996).
M. Matsushita, et al., “MASP-1 (MBL-Associated Serine Protease-1)”, Immunobiol. 199:340-347 (1998).
Y. Zhang, et al., “Lysis via the Lectin Pathway of Complement Activation: minireview and lectin pathway enhancement of endotoxin-initialed hemolysis”, Immunopharmacol. 42:81-90 (1999).
Y, Zhang, et al., “Calcium-Indepentent Haemolysis via the Lectin Pathway of Complement Activation in the Guinea-Pig and Other Species”, Immunol. 97:686-692 (1999).
Hans-Peter Heinz, et al., “Monoclonal Antibodies Against Components of the Classical Pathway of Complement”, Complement Inflamm. 6: 166-174 (1989).
V.M. Holers, “Complement”, In: Clinical Immunology: Principles and Practice, R.R. Rich Ed., Mosby Press, 1996, pp. 383-391.
Vorup-Jensen, et al., “MASP-2, the C3 Convertase Generating Protease of the MBLectin Complement Activating Pathway”, Immunobiol. 199: 348-357 (1998).
C. Suankratay, et al., “Complement Regulation in Innate Immunity and the Acute-Phase Response: Inhibition of Mannan-Binding Lectin-Initialed Complement Cytolysis of C-Reactive Protein”, Clin. Exp. Immunol. 113:353-359 (1998).
C. Suankratay, et al., “Mechanism of Complement-Dependent Haemolysis via the Lection Pathway: Role of the Complement Regulatory Proteins”, Clin. Exp. Immunol. 117:442-448 (1989).
R. Schlinder, et al., “Recombinant C5a Stimulates Transcription Rather Then of Interleukin-1 (IL-1) and Tumor Necrosis Factor: Translational Signal Provided by Lipopolysaccharide or.IL-1 Itself”, Blood 76:1631-1638 (1990).
T. Wiedmer et al., “Participation of Protein Kinases in Complement C5b-9-Induced Shedding of Platelet Plasma Membrane Vesicles”, Blood 78:2880-2886 (1991).
M. P. Fletcher, et al., “C5a-Induced Myocardial Ischemia: Role for CD-18-Dependent PMN Localization and PMN-Platelet Interactions”, Am. J. Pathsiol. 265:h1750-1761 (1993).
S. Nagasawa, et al., “Cleavage of C2 by C1 s into Antigenically Distinct Fragments C2a and C2b: Demonstration of Binding of C2b and C4b”, Proc. Natl. Acad. Sci. (USA) 74:2998-3001 (1977).
E. I. Stenbaeck, et al., “Human Complement Component C2: Production and Characterization of Polyclonal and Monoclonal Antibodies Against C2”, Mol. Immunol. 23:879-886 (1986).
T. J. Oglesby, et al., “Evidence for a C4b Binding Site on the C2b Domain of C2”, J. Immunol. 141:926-931 (1988).
Y. Wang, et al., “Amelioration of Lupus-Like Autoimmune Disease in NZB/W F.sub.1 Mice After Treatment With a Blocking Monoclonal Antibody Specific for Complement Component C5”, Proc. Natl. Acad. Sci. (USA), 1996, 93:8563-8568.
C. S. Rinder, et al., “Blockade of C5a and C5b Generation Inhibits Leukocyte and Platelet Activation During Extracorporeal Circulation”, J. Clin. Invest. 96:1564-1572 (1995).
J.C. K. Fitch, et al., “Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass”, Curculation 100:2499-2506 (1999).
H. L. Lazar, et al., “Total Complement Inhibition: An Effective Strategy to Limit Ischemic Injury During Coronary Revasculaization on Cardiopulmonary Bypass”, Circulation 100:1438-1442 (1999).
T. J. Kroshus, et al., “Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury In an Ex Vivo Model of Pig-To-Human Xenotransplantation”, Transplantation 60:1194-1202 (1995).
J. W. Homeister, et al., “Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart”, J. Immunol. 150: 1055-1064 (1993).
H. F. Weisman, et al., “Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis”, Science 249:146-151 (1990).
E. A. Amsterdam, et al., “Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a during Myocardial Infarction In Pigs”, Am. J. Physiol. 268:H448-H457 (1995).
R. Rabinovici, et al., “Role of Complement in Endotoxin/Platelet-Activating Factor-Induced Lung Injuy”, J. Immunol. 149:1744-1750 (1992).
B. P. Morgan, “Clinical Complementology: Recent Progress and Future Trends”, Eur. J. Clin. Invest. 24:219-228 (1994).
S. M. Canfield, et la., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the C2 Domain and is Modulated by the Hinge Region”, J. Exp. Med. 173:1483-1491 (1991).
Kohler and Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature 256: 495-497 (1975). Y. Xu, et al., “Residue at Position 331 in the IgG1 and IgG4 C2 Domains Contributes to Their Differential Ability to Bind and Activate Complement”, J. Biol. Chem. 269:3469-3474 (1994).
V. L. Pulito, et al., “Humanization and Molecular Modeling of the Anti-CD4 Monoclonal Antibody, OKT4A”, J. Immunol. 156:2840-2850 (1996).
L. Riechmann, et al., “Reshaping Human Antibodies for Therpay”, Nature 332:323-327 (1988).
M. J. Evans, et al., “Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector That Replicates in COS and 293 Cells”, J. Immunol. Meth. 184:123-138 (1995).
S.K. Datta, “Murine Lupus”, Meth. Enzymol. 162:385-413 (1988).
D. J. Salvant, et al., “Experimental Glomerulonephritis”, Meth. En
Genentech Inc.
Jones Day
Wen Sharon
LandOfFree
Method of inhibiting complement activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting complement activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting complement activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635495